Pfizer's (PFE) Paxlovid and Comirnaty Q1 Sales Estimates Lowered at Cantor Fitzgerald, but "Positive Investment Thesis" Maintained, Reiterates Overweight Rating
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $75.00 price target on Pfizer (NYSE: PFE)The analyst comments; "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
